Clinical trial
A Phase 2a, Multi-center, Placebo-Controlled, Randomized, Assessor-blind Study to Assess the Safety & Efficacy of Parenteral TK-90 or Parenteral TK-90 Placebo to Patients Receiving Radiotherapy for Non-Metastatic Squamous Cell Carcinoma of Head and Neck.
NCT05658016 is registered in ClinicalTrials.gov with Tosk, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Multi-center, Placebo-Controlled, Randomized, Assessor-blind Study to Assess the Safety & Efficacy of Parenteral TK-90 or Parenteral TK-90 Placebo to Patients Receiving Radiotherapy for Non-Metastatic Squamous Cell Carcinoma of Head and Neck.
- Lead sponsor
- Tosk, Inc.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 17, 2022
- Completion date
- September 30, 2023
- Enrollment
- 24 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.